HBM Holdings (HKG:2142) expects a profit of between 7.3 million yuan and 22 million yuan for 2024, compared with $22.8 million in 2023, a Friday bourse filing said.
The biotech company attributed the forecast to growth in its recurring revenue, cost control, and partnerships with pharmaceutical and biotech companies worldwide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.